Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes~* Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study~* Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10%~Exclusion Criteria:~* Type 1 Diabetes~* Hepatic (liver) impairment~* Renal (kidney) failure or dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): dapagliflozin 2.5mg + Glimepiride
- 2 (Type: EXPERIMENTAL): dapagliflozin 5mg + Glimepiride
- 3 (Type: EXPERIMENTAL): dapagliflozin 10mg + Glimepiride
- 4 (Type: PLACEBO_COMPARATOR): Placebo + Glimepiride

Based on this trial design, predict the completion outcome and termination type (if applicable).